Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630251 | 0.90 | — | — | |
| SCHEMBL18032583 | 0.79 | TSHR (0.44) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL8764126 | 0.77 | TSHR (0.42) | TSHRTHRBAPAF1HSP90AA1RAD52 | |
| SCHEMBL12501155 | 0.77 | TSHR (0.42) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL7052076 | 0.77 | TSHR (0.42) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL10878964 | 0.74 | TSHR (0.39) | TSHRTHRBLMNASLC22A1 | |
| SCHEMBL10534051 | 0.73 | TSHR (0.38) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL10913195 | 0.73 | TSHR (0.38) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL29190711 | 0.73 | TSHR (0.35) | TSHRTHRBDNM1ALDH1A1MEN1 | |
| SCHEMBL10536236 | 0.73 | TSHR (0.38) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017102055-A1 | METHOD FOR PRODUCING SALTS WITH MONOFLUOROTRICYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| US-9399650-B2 | Method for producing salts having monofluoro-tricyanoborate anions | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| WO-2016074760-A1 | METHOD FOR PRODUCING SALTS HAVING HYDRIDOCYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2016-05-19 | — | — | WO | disclosed |
| US-20160130286-A1 | METHOD FOR PRODUCING SALTS HAVING MONOFLUORO-TRICYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130285-A1 | METHOD FOR PRODUCING SALTS HAVING HYDRIDOCYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| EP-3008074-A1 | METHOD FOR PRODUCING SALTS HAVING HYDRIDOCYANOBORATE ANIONS | Merck Patent GmbH (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-3008075-A1 | METHOD FOR PRODUCING SALTS HAVING MONOFLUORO-TRICYANOBORATE ANIONS | Merck Patent GmbH (DE) | 2016-04-20 | — | — | EP | disclosed |
| WO-2016015811-A1 | METHOD FOR PRODUCING SALTS HAVING HYDRIDOCYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
| WO-2015185178-A1 | METHOD FOR PREPARING TETRACYANOBORATE SALTS | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015185183-A1 | METHOD FOR PREPARING SALTS CONTAINING MONOHYDRIDO-CYANO-BORATE ANIONS | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015022048-A1 | HEXACYANODIBORATES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
| WO-2014198402-A1 | METHOD FOR PRODUCING SALTS HAVING HYDRIDOCYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198401-A1 | METHOD FOR PRODUCING SALTS HAVING MONOFLUORO-TRICYANOBORATE ANIONS | MERCK PATENT GMBH (DE) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130286-A1 | METHOD FOR PRODUCING SALTS HAVING MONOFLUORO-TRICYANOBORATE ANIONS | SLC6A6, TBCB, CA6 | TSHR 2937/4885THRB 3159/4885APAF1 2206/4885 |
| US-20160130285-A1 | METHOD FOR PRODUCING SALTS HAVING HYDRIDOCYANOBORATE ANIONS | HDHD5, SLC6A6, MAGT1 | TSHR 2549/4885THRB 2774/4885APAF1 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.